CVS Health Corporation (NYSE:CVS)

CVS Health Corporation is a pharmacy innovation company. Its offerings include pharmacy benefit management services, mail order, retail and specialty pharmacy, disease management programs, and retail clinics. The Company serves employers, insurance companies, unions, government employee groups, managed care organizations and other sponsors of health benefit plans, and individuals under the CVS Caremark Pharmacy Services, Caremark, CVS Caremark, CarePlus CVS/pharmacy, RxAmerica, Accordant, SilverScript, and Novologix names. CVS Health Corporation, formerly known as CVS Caremark Corporation, is headquartered in Woonsocket, Rhode Island.

CVS Health Corporation (NYSE:CVS)’s Financial Overview

CVS Health Corporation (NYSE:CVS) surged 1.47% yesterday to close its trading session at $75.88. The company has 1 year Price Target of $88.02. CVS Health Corporation has 52-Week high of $106.67 and 52-Week Low of $69.3. The stock touched its 52-Week High on May 9, 2016 and 52-Week Low on Nov 8, 2016. The stock traded with the volume of 8.65 Million shares yesterday. The firm shows the market capitalization of $80.92 Billion.

CVS Health Corporation (NYSE:CVS) reported its last quarterly earnings on Sep 16 where the firm reported its Actual EPS of $1.64/share against the analyst consensus estimate of $1.57/share. The difference between the actual and expected EPS is $0.07 a share with a surprise factor of 4.5%.

The firm is trading with SMA20 of -1.8 Percent, SMA50 of -9.1 Percent and SMA200 of -19.05 percent. CVS Health Corporation has P/S value of 0.47 while its P/B value stands at 2.25. Similarly, the company has Return on Assets of 5.1 percent, Return on Equity of 13.2 percent and Return on Investment of 9.4 Percent. The company shows Gross Margin and Operating Margin of 16.5 percent and 5.1 percent respectively.

Many brokerage firms are involved in issuing their ratings on CVS Health Corporation (NYSE:CVS). On 20-Jun-16 Morgan Stanley Downgrade CVS Health Corporation Stock  to Equal-Weight. Another firm also rated the stock on 3-Feb-16 where Atlantic Equities Initiated the stock to Overweight.

The Stock currently has Analyst’ mean Recommendation of 1.9 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 22 analysts offering 12-month price forecasts for CVS Caremark have a median target of 86.75, with a high estimate of 115.00 and a low estimate of 80.00. The median estimate represents a +14.33% increase from the last price of 75.88.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)

Ariad Pharmaceuticals is engaged in the discovery and development of novel pharmaceuticals based on intracellular signaling technology.  The Company has established highly integrated capabilities in functional genomics, molecular cell biology, structure based drug design, combinatorial chemistry and pharmacology.  The company is developing small-molecule drugs that block signal transduction pathways in cells responsible for osteoporosis, and immune and inflammatory diseases.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)’s Financial Outlook

The 11 analysts offering 12-month price forecasts for ARIAD Pharmaceuticals Inc have a median target of 11.00, with a high estimate of 22.00 and a low estimate of 7.00. The median estimate represents a -20.29% decrease from the last price of 13.80.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, Ariad Pharmaceuticals Inc. has a Consensus Recommendation of 2.33. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock gained 0.73% and closed its last trading session at $13.8. The company has the market capitalization of $2.68 Billion. The stock has 52-week high of $14.42 and 52-Week low of $4.37. The firm touched its 52-Week high on Oct 10, 2016 and 52-Week low on Feb 11, 2016. The company has volume of 8.63 Million shares. The company has a total of 194.2 Million shares outstanding.

Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) in the last quarter reported its actual EPS of $-0.14/share where the analyst estimated EPS was $-0.19/share. The difference between the actual and Estimated EPS is $0.05. This shows a surprise factor of 26.3 percent.

The company has YTD performance of 120.8 percent. Beta for Ariad Pharmaceuticals Inc. stands at 2.1 while its ATR (average true range) is 0.72. The company has Weekly Volatility of 5.23%% and Monthly Volatility of 5.60%%.

Ariad Pharmaceuticals Inc. has distance from 20-day Simple Moving Average (SMA20) of 17.51%, Distance from 50-Day Simple Moving Average of 14.58 percent and Distance from 200-Day Simple Moving Average of 55.07%.

The Company currently has ROA (Return on Assets) of -5.4 percent, Return on Equity (ROE) of 37.1 Percent and Return on Investment (ROI) of -62.9% with Gross margin of 98.3 percent and Operating & Profit margin of -73.6% and -17% respectively.

 

SHARE